Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15800060 | 0.84 | HDAC1 (0.52) | HDAC1CHRM4ACHEOPRD1MCHR1 | |
| SCHEMBL15800205 | 0.83 | KDM4E (0.67) | HDAC1ACHEDRD2KCNH2CHRM2 | |
| SCHEMBL18173429 | 0.82 | LTA4H (0.56) | CHRM4DRD2KCNH2 | |
| SCHEMBL13726472 | 0.82 | HRH3 (0.51) | HDAC1CHRM4ACHEOPRD1DRD2 | |
| SCHEMBL20527292 | 0.81 | GAA (0.64) | HDAC1OPRD1KCNH2HRH3KDM4E | |
| SCHEMBL13728322 | 0.77 | HRH3 (0.61) | HDAC1MCHR1HRH3KDM4EALDH1A1 | |
| SCHEMBL28175300 | 0.77 | KDM4E (0.50) | HDAC1CHRM4DRD2HRH3KDM4E | |
| SCHEMBL14475381 | 0.75 | DRD2 (0.48) | HDAC1MCHR1DRD2KCNH2KDM4E | |
| SCHEMBL8319123 | 0.75 | ALDH1A1 (0.59) | ACHEDRD2HRH3ALDH1A1 | |
| SCHEMBL27997282 | 0.74 | KDM4E (0.61) | ACHEMCHR1CYP2D6CHRM2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3286172-B1 | LSD1 INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS INC (US) | 2019-06-12 | — | — | EP | claimed |
| US-20180290976-A1 | LSD1 INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2018-10-11 | — | — | US | claimed |
| EP-3286172-B1 | LSD1 INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS INC (US) | 2019-06-12 | — | — | EP | disclosed |
| US-20180290976-A1 | LSD1 INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2018-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180290976-A1 | LSD1 INHIBITORS AND USES THEREOF | KDM1B, KDM1A, KDM2A | HDAC1 11/4885CHRM4 3221/4885ACHE 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.